 |
|
|
| |
TBR-652, a Potent Dual CCR5/CCR2 Antagonist in Phase 2 Development for Treatment of HIV Infection - Inflammation
|
| |
| |
Reported by Jules Levin
David E. Martin, PharmD*
Tobira Therapeutics, Inc.
*On behalf of TBR-652-2-201 Study Team
XVIII International AIDS Conference, Vienna, Austria 20 July 2010
|
| |
|
|
|
|
|
